GlassScriptPhysician profile
Romana Kulikova
NPI 1245263441
$3,670.72
in general payments reported to CMS, 2019-2025
35 companies · $1,432 in 2025
The $1,432 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $387 · 2021: $456 · 2022: $372 · 2023: $390 · 2024: $276 · 2025: $1,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857 · Travel and Lodging: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.49 |
| Travel and Lodging | $241.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $449.09 | 2024-2025 | Cobenfy |
| Eisai INC. | $381.27 | 2019-2023 | |
| Tris Pharma INC | $318.98 | 2020-2023 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $295.11 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $227.65 | 2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $210.71 | 2025 | Caplyta |
| Neurelis, INC. | $190.72 | 2020-2023 | Valtoco |
| Ironshore Pharmaceuticals INC. | $154.22 | 2020-2024 | Jornay Pm |
| Biogen, INC. | $140.67 | 2020-2022 | |
| Corium, LLC | $125.30 | 2022-2024 | Azstarys |
| Allergan, INC. | $118.70 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $114.13 | 2025 | |
| Acadia Pharmaceuticals INC | $87.62 | 2025 | Nuplazid |
| Vanda Pharmaceuticals INC. | $80.98 | 2024-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $80.02 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $60.90 | 2024-2025 | Aristada, Lybalvi |
| Ucb, INC. | $60.35 | 2021-2022 | |
| Ns Pharma, INC. | $49.12 | 2023 | Viltepso |
| Janssen Pharmaceuticals, INC | $48.90 | 2024-2025 | Invega Sustenna |
| Abbvie INC. | $42.41 | 2022 | |
| Neos Therapeutics, LP | $41.85 | 2019 | |
| Lilly USA, LLC | $40.79 | 2025 | Kisunla |
| Aprecia Pharmaceuticals, LLC | $38.54 | 2020-2022 | |
| Greenwich Biosciences, INC. | $37.42 | 2019-2021 | |
| Aquestive Therapeutics, INC. | $37.20 | 2019 | |
| Biomarin Pharmaceutical INC. | $34.42 | 2023 | Brineura |
| Jazz Pharmaceuticals INC. | $29.40 | 2022-2023 | |
| Lundbeck LLC | $28.72 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $28.03 | 2021-2022 | |
| Adlon Therapeutics L.P. | $27.83 | 2020-2021 | |
| Integra Lifesciences Corporation | $26.98 | 2023 | Codman Certas, Cusa Clarity, Duraseal Exact Spinal Sealant System |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $16.88 | 2019 | |
| Immedica Pharma US, INC. | $16.84 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.21 | 2025 | |
| Vertical Pharmaceuticals, LLC | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romana Kulikova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.